Nutraceutix#s L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism

Food and Healthcare Press Releases Wednesday July 29, 2015 12:00
REDMOND, Washington--29 Jul--PRNewswire/InfoQuest

A German Diabetes Center clinical study found that daily ingestion of Nutraceutix's L. reuteri probiotic enriches human gut microbiota and modifies gut production of protein factors that increase insulin secretion.   The study involved daily administration of Nutraceutix's L. reuteri strain (ATCC strain SD-5865) in tablets using the patented BIO-tract(R) delivery technology that protects live probiotics from damage by stomach acid on their way to the intestinal tract.

Logo - http://photos.prnewswire.com/prnh/20111006/SF81647LOGO

The randomized, double-blind, placebo-controlled study compared secretion of insulin, C-peptide, and proglucagon-derived peptides and pancreatic beta-cell function in glucose-stimulated non-diabetic participants to measure incretin effect.   Participants took L. reuteri tablets or placebo tablets daily over a four-week period.   People taking the L. reuteri had increased glucose-stimulated insulin secretion by 49%, C-peptide secretion by 55%, GLP-1 release by 76%, GLP-2 release by 43%, and altered beta-cell function relative to people taking the placebo.   In a related presentation before the American Diabetes Association, the study's primary researcher concluded, "probiotic treatment may improve incretin-mediated beta-cell function, which could be beneficial for the treatment of glucose intolerance or overt type 2 diabetes."

Detailed gut microbiota composition analysis of the study participants was done before and after the study.   After the study, all those taking L. reuteri BIO-tract tablets had detectable L. reuteri in their stool samples, while those tested from the placebo group did not.   No participants reported adverse effects.

The study article was published online along with supplementary data, at the American Diabetes Association(R) (ADA) Diabetes Care(R) website in June 2015, doi: 10.2337/dc14-2690.   The referenced presentation was made at the 72nd Scientific Sessions of the ADA, Philadelphia, PA, in June 2012.   A webcast of the presentation can be found at the professional.diabetes.org website.

Nutraceutix is a Registered GMP contract manufacturer of probiotics in bulk powder, and in standard and advanced capsule and tablet forms.   Nutraceutix's BIO-tract technology is protected by U.S. Patent Nos. 8,540,980 and 8,007,777, and over 30 international patents.

Disclaimer:   BIO-tract is a registered trademark of Nutraceutix.   Nutraceutix is not affiliated with the American Diabetes Association.   The American Diabetes Association(R) and Diabetes Care(R) are trademarks owned by their respective holders.   Use of them does not imply affiliation or endorsement by them.


Latest Press Release

Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in...

UK Schools Rank Last in Providing Oral Health Education, FDI Survey of 13 Countries Says

Today on World Oral Health Day (WOHD), FDI World Dental Federation (FDI) released the results of a survey from 13 countries, which asked parents with children aged 5–16 if their child's school provided lessons on good oral care. Poor oral health...

Merck Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology

- Collaboration agreement enables Merck access to Iktos AI technology across three drug discovery projects - Generative modelling AI technology enables rapid and cost-effective design of novel drugs - Agreement is part of Merck's R&D strategy to...

Oxford Nanopore Launches Flongle for Rapid, Smaller DNA/RNA Sequencing Tests in Any Environment

Oxford Nanopore has today made Flongle starter packs available to purchase https://store.nanoporetech.com/flongle.html, after initial testing in an early-access programme. Flongle introduces a new paradigm of smaller, on-demand DNA or RNA sequencing...

FDI: Endodontics White Paper Calls for Treatment to Consider Impact on Patient Health and Well-being

FDI World Dental Federation (FDI) released its first white paper on endodontic care today, providing an important resource for dentists, national dental associations (NDAs) and other oral health actors. (Logo:...

Related Topics